We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sotagliflozin

News List

Addition of Sotagliflozin for T1DM Alters Renal Hemodynamics drugs
August 08, 2019
Sotagliflozin (SOTA), a dual sodium-glucose cotransporter 1 inhibitor (SGLT1i) and SGLT2i, is associated with short- and long-term renal hemodynamic changes in patients with type 1 diabetes...
EMA agrees to review Sanofi's filing for dual SGLT-1/2 inhibitor sotagliflozin in type 1 diabetes firstwordpharma
March 30, 2018
Sanofi announced Thursday that the European Medicines Agency (EMA) has accepted to review its marketing application for the experimental oral drug sotagliflozin
Lexicon Reports Additional Positive Data from Sotagliflozin Pivotal Phase 3 Study pharmaceutical-technology
August 16, 2017
Lexicon Pharmaceuticals announced additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.
Lexicon Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin americanpharmaceuticalreview
May 12, 2017
Lexicon Pharmaceuticals announced additional positive data from the Phase 3 inTandem1 study.